Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 1;135(3):460-473.
doi: 10.1213/ANE.0000000000006039. Epub 2022 Aug 17.

Update on Applications and Limitations of Perioperative Tranexamic Acid

Prakash A Patel  1 , Julie A Wyrobek  2 , Alexander J Butwick  3 , Evan G Pivalizza  4 , Gregory M T Hare  5 , C David Mazer  5 , Susan M Goobie  6
Affiliations
Review

Update on Applications and Limitations of Perioperative Tranexamic Acid

Prakash A Patel et al. Anesth Analg. .

Abstract

Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on patient blood management, TXA has become an integral aspect of perioperative blood conservation strategies. While clinical applications of TXA in the perioperative period are expanding, routine use in select clinical scenarios should be supported by evidence for efficacy. Furthermore, questions regarding optimal dosing without increased risk of adverse events such as thrombosis or seizures should be answered. Therefore, ongoing investigations into TXA utilization in cardiac surgery, obstetrics, acute trauma, orthopedic surgery, neurosurgery, pediatric surgery, and other perioperative settings continue. The aim of this review is to provide an update on the current applications and limitations of TXA use in the perioperative period.

Trial registration: ClinicalTrials.gov NCT03782350 NCT02840097.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015;47:339–350.
    1. Watts G. Utako Okamoto. Lancet. 2016;387:2286.
    1. Tengborn L, Blombäck M, Berntorp E. Tranexamic acid–an old drug still going strong and making a revival. Thromb Res. 2015;135:231–242.
    1. Pharmacia & Upjohn Company, a subsidiary of Pfizer Inc. CYKLOKAPRON (tranexamic acid) [package insert]. U.S. Food and Drug Administration website. 2021. Accessed May 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019281Orig1s04... .
    1. Myles PS, Smith JA, Forbes A, et al.; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376:136–148.

Publication types

MeSH terms

Associated data

LinkOut - more resources